Your browser doesn't support javascript.

Portal Regional da BVS

Informação e Conhecimento para a Saúde

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma.

Protein Pept Lett; 2018 05 30.
Artigo em Inglês | MEDLINE | ID: mdl-29848258
Targeted therapy has been widely used in the treatment of patients with metastatic renal cell carcinoma (mRCC). The current available therapies focus on the inhibition of angiogenesis through targeting the vascular endothelial growth factor receptor (VEGFR), and protein kinase such as the mammalian target of rapamycin (mTOR). Compared with other traditional chemotherapies and radiotherapies, targeted therapies dramatically improved progression-free survival (PFS). However, the microenvironment o